Skip to content

Corvus Pharmaceuticals

US · CRVS #3339 by market cap Listed 2016
10.41 -0.15 -1.42%
Live - 5344 symbols - heartbeat 528s ago · 2026-10-08 08:12
Pre-market 10.13 -2.69%
After-hours 10.52 +1.06%
Market cap
875.70M
P/B
3.89
EPS
-0.53
Reader sentiment Are you bullish or bearish on CRVS?

Anonymous reader poll. Unscientific, not investment advice.

Recent news

  • Rating change
    Barclays Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Raises Target Price to $28
    Market Newswire · 2026/1/21
  • Rating change
    H.C. Wainwright Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Raises Target Price to $27
    Market Newswire · 2026/1/21
  • Rating change
    Oppenheimer Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Raises Target Price to $33
    Market Newswire · 2026/3/13
  • Rating change
    Oppenheimer Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Raises Target Price to $32
    Market Newswire · 2026/1/21
  • Rating change
    Jefferies Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Raises Target Price to $42
    Market Newswire · 2026/1/23
  • Rating change
    Mizuho Securities Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Maintains Target Price $13
    Market Newswire · 2025/12/10
  • Rating change
    Mizuho Securities Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Raises Target Price to $20
    Market Newswire · 2026/1/21
  • Barclays Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Maintains Target Price $28
    Market Newswire · 2026/8/7
  • Rating change
    Mizuho Securities Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Raises Target Price to $13
    Market Newswire · 2025/10/29
  • Rating change
    Mizuho Securities Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Raises Target Price to $30
    Market Newswire · 2026/1/29
  • Rating change
    H.C. Wainwright Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Maintains Target Price $11
    Market Newswire · 2025/11/5
  • Rating change
    Goldman Sachs Initiates Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Announces Target Price $40
    Market Newswire · 2026/4/17
  • Rating change
    Goldman Sachs Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Maintains Target Price $40
    Market Newswire · 2026/5/12
  • Mizuho Securities Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Maintains Target Price $30
    Market Newswire · 2026/8/12
  • Rating change
    Oppenheimer Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Cuts Target Price to $15
    Market Newswire · 2025/8/8
  • H.C. Wainwright Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Maintains Target Price $27
    Market Newswire · 2026/8/10
  • Rating change
    Oppenheimer Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Maintains Target Price $33
    Market Newswire · 2026/5/8
  • A Quick Look at Today's Ratings for Corvus Pharmaceuticals(CRVS.US), With a Forecast Between $27 to $40
    Market Newswire · 2026/5/15
  • Corvus Pharmaceuticals (CRVS.US) will release its earnings report after market close on August 6.
    Market Newswire · 2026/8/1
  • Rating change
    Barclays Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Maintains Target Price $16
    Market Newswire · 2025/11/5

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-10-08 08:12:11 · For reference only, not investment advice and not tailored to your situation.